Since the 2018 guideline’s publication, additional non-statin therapies such as bempedoic acid, evinacumab, and inclisiran, have been approved by the FDA for the management of hypercholesterolemia.
Mickenzie Meyers, PharmD Candidate
Advertisement
Articles by Mickenzie Meyers, PharmD Candidate
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
A Review of Antibody-Drug Conjugates for the Treatment of Urothelial Carcinoma: The Rise of Enfortumab Vedotin
2
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
3
Low-Dose Aspirin Linked to Lower Cardiovascular Risk in Type 2 Diabetes
4
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
5
